FarmerJ.B., KennedyI., LevyG.P., MarshallR.J.Pharmacology of AH5158: a drug which blocks both β- and α-adrenoceptors. Br J Pharmacol1972; 45: 660–675.
2.
RichardsD.A., PrichardB.N.C.Clinical pharmacology of labetalol. Br J Pharmacol1979; 8: 89S–93S.
3.
GoodmanL.S., GilmanA.The Pharmacological Basis of Therapeutics.Macmillan, New York1980; 197.
4.
RichardsD.A., PrichardB.N.C., BoakesA.J., TuckmanJ., KnightE.J.Pharmacological basis for antihypertensive effects of intravenous labetalol. Br Heart J1977; 39: 99–106.
5.
RossE.J., PrichardB.N.C., KaufmanL., RobertsonA.I.G., HarriesB.J.Preoperative and operative management of patients with phaeochromocytoma. Br Med J1967; 1: 191–198.
6.
Da PradaM., ZurcherG.Simultaneous radioenzymatic determination of plasma and tissue adrenaline, noradrenaline and dopamine within the femtomole range. Life Sci1976; 19: 1161–1174.
7.
RussellW.J., MorrisR.G., FrewinD.B., DrewS.E.Changes in plasma catecholamine concentrations during endotracheal intubation. Br J Anaesth1981; 53: 837–839.
8.
BaileyR.R.Labetalol in the treatment of a patient with phaeochromocytoma: A case report. Br J Clin Pharmacol1979; 8: 141S–142S.
